Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων
Keypoints
t-AML, sAML, AML-MRC can be nowadays clinically, morphologically and genetically (cytogenetics, somatic mut) identified
In these pts (most > 60 y of age) CPX-351 enables efficient and safe delivery of intensive chemotherapy
Consolidation with HCT in these pts is curative with real...
4o Eκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών: Πως ενσωματώνονται οι θεραπείες στόχευσης, η ανοσοθεραπεία και οι κυτταρικές θεραπείες στον σύγχρονο θεραπευτικό αλγόριθμο.
Επισυνάπτεται η ομιλία της Λίγκα Μαρία Ιατρού Αιματολόγου της ΜΜΜΟ ΠΓΝΠ με τίτλο "Επιλογή δότη στην απλοταυτόσημη μεταμόσχευση"
Παρουσιαστής:...
4o Eκπαιδευτικό Σεμινάριο στη Μεταμόσχευση Μυελού των Οστών: Πως ενσωματώνονται οι θεραπείες στόχευσης, η ανοσοθεραπεία και οι κυτταρικές θεραπείες στον σύγχρονο θεραπευτικό αλγόριθμο.
Επισυνάπτεται η ομιλία του Τσοκάνα Δημητρίου, Ιατρού Αιματολόγου της ΜΜΜΟ ΠΓΝΠ με τίτλο "Επαναπροσδιορίζοντας τις θεραπείες επιλογής, βελτιώνοντας...
We discussed the new findings of AML MRC, secondary AML and the therapeutic option with Vyxeos
Presenter Spyridonidis
Particpants: Tsokanas, Liga, Valera
Presentation of a consensus document from the European LeukemiaNet MRD Working Party | Blood | American Society of Hematology
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 40 mins
Presenter: Gakis Georgios, 4th year undergraduate MD student
Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas
Duration: 30 mins
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, A. Christopoulou, E. Sagiadinou, V. Zacharioudaki, E.Triantafyllou
Duration: 40 mins
Indications for haematopoietic cell transplantation for
haematological diseases, solid tumours and immune disorders:
current practice in Europe, 2022
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 30mins
We discussed a case of PCNSL in an HIV patient and reviewed the literaure about the pathogenic role of EBV. In such immunocomprisised patients, the detection of EBV transcript in all of the...
Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas
Duration: 20 mins
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou Duration: 15 mins
Various reorts suggest the preferiantial use of Ankinra ver tocilizumab
in CAR T-cell associated toxicities
2022-W14: Early bilirubinemia after allogeneic stem cell transplantation—an endothelial complication
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas
Duration: 25 mins
Hyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and
endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on
posttransplant outcomes. Maximum total...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou Duration: 20 mins
The outcome of refractory/relapsed (R/R) acute leukemias is still dismal and their treatment represents an unmet clinical need.
However, allogeneic transplantation (allo-HSCT) remains the only potentially curative approach...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou
Duration: 20 mins
Pre-harvest autologous blood collection from bone marrow (BM) donors is performed to meet potential post-operative transfusion needs. This study examines the impact of autologous blood transfusion on BM...
Ομιλητής: Vincent van Dam
Συμμετέχοντες: Καθ. Α. Σπυριδωνίδης, Λίγκα Μαρία, Τσοκάνας Δημήτρης, Σαγιαδινού Ελευθερία, Ζαχαριουδάκη Βασιλική, Κεφάλα Διονυσία
Στα πλαίσια του Μεταπτυχιακού Προγραμματος «Cell and Gene Therapies: from bench to bedside and Good Manufacturing Practices» πραγματοποιήθηκε τηλεδιάσκεψη με τίτλο "Elements of a QA...
Presenter: Evangelia Arampatzi, CRA
Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Sagiadinou E., Panagi Z.
Today, on 16 March 2022 training about study protocol "AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter, Study to Evaluate Efficacy, Safety and Tolerability of Axatilimab at 3...
Presenter: Gakis George
Participants: Prof Spyridonidis, Dr Liga, Dr Tsokanas, E. Sagiadinou, A. Christopoulou
An abstact on behalf of 28th SCHMS congress, presented by Medical student George Gakis.
Chimeric antigen receptor (CAR) T-cells have revolutionized the
standards of care for patients with hematologic malignancies....
A study on behalf of the Acute Leukemia Working Party of the EBMT, presented by Prof. Spyridonidis
Is 8- instead of 12-Gray sufficient for acute lymphoblastic ,leukemia
patients transplanted in first complete remission?
Total body irradiation (TBI) continues to be an important part...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z.
Post-transplant cyclophosphamide (PTCY) is increasingly used for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLA-matched unrelated donor (MUD) as an alternative to the standard anti-thymocyte globulin...
Presenters: Dr Wendy Stock, Dr Scott Howard, Dr Stephen Hunger, Dr Dan Douer
Participants: Prof. Spryridonidis
See the on-demand webcast of ASH2021 titled “Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience”
On ASH2021 symposium the treatment of adult patients with Acute Lymphoblastic Leukemia with pegaspargase was discussed, as well...
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Tsokanas, Sagiadinou E., Christopoulou A., Panagi Z.
Patients with DLBCL primary refractory or relapsed ≤ 12 mo after first-line (1L) therapy may have poor outcomes with SOC, including salvage CT and ASCT, which underscores a...